All NEW Investors: Your gift matched $ for $ this week! GIVE NOW

The upside of the vaccine rollout for the companies making shots

May 3, 2021
The resulting goodwill may prove useful to Pfizer and Moderna.
Karen Andersen, who covers biotech at Morningstar, says the potential sale of booster shots to ward off variants of COVID-19 could be profitable for Pfizer and Moderna.
Matic Zorman/Getty Images

Vaccine delivery across the country faces complex supply chain challenges

Dec 10, 2020
Within 24 hours of emergency authorization from the Food and Drug Administration, the vaccine maker Pfizer plans to move the product to patients nationwide.
A worker prepares boxes of vaccines before shipment at a French pharmaceutical company world distribution center.
Joel Saget/AFP via Getty Images

Moderna asking U.S., European regulators to OK vaccine

Nov 30, 2020
Moderna is just behind Pfizer and its German partner BioNTech in seeking to begin vaccinations in the U.S. in December.
Joel Saget/AFP via Getty Images

AstraZeneca vaccine is third to show promising data in unprecedented hurry-up race

Nov 23, 2020
The COVID-19 vaccine is being produced so quickly due to a combination of factors involving the research community, government, industry and the public.
A volunteer receives a COVID-19 vaccination at the Research Centers of America in Hollywood, Florida.
Chandan Khanna/AFP via Getty Images

How might COVID-19 vaccine makers compete in the marketplace?

Nov 17, 2020
At first, COVID-19 vaccines won't be marketed in the usual sense, because the government will be the main buyer.
A volunteer takes part in a COVID-19 vaccination trial this summer in Hollywood, Florida.
Joe Raedle/Getty Images